Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a combination medicine approved by the FDA in 2024. Alyftrek is approved to treat people ages 6 and older who have ...

I also like Vertex's opportunity with its newest cystic fibrosis (CF) drug, Alyftrek, which won U.S. regulatory approval in December 2024. Granted, Alyftrek will probably cannibalize sales from ...

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

But now UK drugs regulator MHRA have approved the new Vertex pill Alyftrek and it's so advanced, trials show patients no longer show up as having CF on vital 'sweat tests'. Now we can reveal this ...

The recent selloff has GreensKeeper excited about the price declines. Click here to read on to learn about our response to ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

That number stands at 33% in other countries. Vertex recently earned approval for yet another CF treatment, Alyftrek, that is just as effective while requiring one dose per day (versus two for ...

This progress, along with the recent approval of ALYFTREK in the UK for cystic fibrosis, might have supported the stock's strength despite broader market uncertainties and a 1.8% decline over the ...